SG11201707592TA - A serotype cross-reactive, dengue neutralizing antibody and uses thereof - Google Patents

A serotype cross-reactive, dengue neutralizing antibody and uses thereof

Info

Publication number
SG11201707592TA
SG11201707592TA SG11201707592TA SG11201707592TA SG11201707592TA SG 11201707592T A SG11201707592T A SG 11201707592TA SG 11201707592T A SG11201707592T A SG 11201707592TA SG 11201707592T A SG11201707592T A SG 11201707592TA SG 11201707592T A SG11201707592T A SG 11201707592TA
Authority
SG
Singapore
Prior art keywords
reactive
neutralizing antibody
serotype cross
dengue neutralizing
dengue
Prior art date
Application number
SG11201707592TA
Other languages
English (en)
Inventor
Cheng-I Wang
Katja Fink
Paul Macary
Roland Zuest
Meihui Xu
Original Assignee
Agency Science Tech & Res
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Nat Univ Singapore filed Critical Agency Science Tech & Res
Publication of SG11201707592TA publication Critical patent/SG11201707592TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201707592TA 2015-03-17 2016-03-17 A serotype cross-reactive, dengue neutralizing antibody and uses thereof SG11201707592TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201502068V 2015-03-17
PCT/SG2016/050124 WO2016148653A1 (en) 2015-03-17 2016-03-17 A serotype cross-reactive, dengue neutralizing antibody and uses thereof

Publications (1)

Publication Number Publication Date
SG11201707592TA true SG11201707592TA (en) 2017-10-30

Family

ID=56920185

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707592TA SG11201707592TA (en) 2015-03-17 2016-03-17 A serotype cross-reactive, dengue neutralizing antibody and uses thereof

Country Status (6)

Country Link
US (1) US10316078B2 (cg-RX-API-DMAC7.html)
EP (1) EP3271390B1 (cg-RX-API-DMAC7.html)
JP (1) JP6957355B2 (cg-RX-API-DMAC7.html)
CN (1) CN107531779B (cg-RX-API-DMAC7.html)
SG (1) SG11201707592TA (cg-RX-API-DMAC7.html)
WO (1) WO2016148653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) * 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
TWI827585B (zh) * 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
TWI737918B (zh) * 2018-06-12 2021-09-01 國防醫學院 抗登革病毒抗體及其應用
US10526398B2 (en) * 2018-06-12 2020-01-07 National Defense Medical Center Anti-dengue virus antibodies and applications thereof
CN109929033B (zh) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 一种特异性结合四种血清型登革病毒的人源抗体
CN115697392B (zh) * 2020-06-28 2026-03-13 神州细胞工程有限公司 一种降低病毒ade效应的方法
JP7286070B2 (ja) * 2021-01-31 2023-06-05 株式会社バランス・イースト 検査システム、検査方法、プログラム、およびコンピュータが読み取り可能な記憶媒体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211477A1 (en) 2000-10-05 2002-04-15 Case Western Reserve University Suppressor of human breast cancer cell growth
US8470976B2 (en) 2006-06-17 2013-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting macromolecules into the nucleus
JP2010527939A (ja) * 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド 中和抗体
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US20140349321A1 (en) 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US9556254B2 (en) * 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
JP6764348B2 (ja) * 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用

Also Published As

Publication number Publication date
CN107531779A (zh) 2018-01-02
JP2018514193A (ja) 2018-06-07
EP3271390B1 (en) 2023-09-27
JP6957355B2 (ja) 2021-11-02
EP3271390A4 (en) 2018-08-08
CN107531779B (zh) 2021-04-13
EP3271390A1 (en) 2018-01-24
US10316078B2 (en) 2019-06-11
WO2016148653A1 (en) 2016-09-22
US20180072798A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
IL320713A (en) Antibodies, uses and methods
IL274921A (en) BCMA-directed chimeric antigen receptor and uses thereof
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
HUE048313T2 (hu) Anti-TIGIT antitestek, anti-PVRIG antitestek és kombinációik
ZA201701168B (en) Antibodies, compositions, and uses
ZA201704117B (en) Cd47 antibodies, methods, and uses
EP3271390A4 (en) A serotype cross-reactive, dengue neutralizing antibody and uses thereof
LT3356411T (lt) Bispecifiniai antikūnai, specifiniai pd1 ir tim3
EP3200823A4 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
IL252430B1 (en) Antibodies, uses and methods
GB201614162D0 (en) Antibodies, uses thereof and conjugates thereof
SI3220947T1 (sl) Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe
GB201612650D0 (en) Program compiler, linker and method
IL257434A (en) Mrka polypeptides, antibodies, and uses thereof
PT3288575T (pt) Complexo de proteína-melanina bioassimilável, sua preparação e utilizações
IL249073A0 (en) Cytin-glucan complex, its preparation and uses
GB201609866D0 (en) Antibodies, uses thereof and conjugates thereof
GB201708105D0 (en) Antibodies, uses thereof and conjugates thereof
GB201618515D0 (en) Combinations comprising antibodies, uses and methods
GB201413950D0 (en) Antibodies, uses & methods
GB201400597D0 (en) Antibodies, uses & methods